Compare · GLS vs MRNA
GLS vs MRNA
Side-by-side comparison of Gelesis Holdings Inc. (GLS) and Moderna Inc. (MRNA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GLS and MRNA operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- MRNA is the larger of the two at $56.02B, about 164.0x GLS ($341.6M).
- MRNA has hit the wire 20 times in the past 4 weeks while GLS has been quiet.
- MRNA has more recent analyst coverage (25 ratings vs 0 for GLS).
- Company
- Gelesis Holdings Inc.
- Moderna Inc.
- Price
- $0.16-3.95%
- $140.21-3.65%
- Market cap
- $341.6M
- $56.02B
- 1M return
- -
- +137.08%
- 1Y return
- -
- +464.34%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NYSE
- NASDAQ
- IPO
- 2020
- 2018
- News (4w)
- 0
- 20
- Recent ratings
- 0
- 25
Gelesis Holdings Inc.
Gelesis Holdings Inc., a commercial stage biotherapeutics company, developing a biomimicry to treat the genesis of obesity and GI-related chronic diseases. The company also provides PLENITY, an orally administered, non-stimulant, and non-systemic aid for weight management. In addition, it offers a product for obesity and overweight and a pipeline with potential therapies for non-alcoholic fatty liver disease/non-alcoholic steatohepatitis, type 2 diabetes, and GS500 for Functional Constipation. Gelesis Holdings Inc. was incorporated in 2006 and is headquartered in Boston, Massachusetts.
Moderna Inc.
Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, the Biomedical Advanced Research and Development Authority, the Defense Advanced Research Projects Agency, the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, the Coalition for Epidemic Preparedness Innovations, and Bill & Melinda Gates Foundation. Moderna, Inc. also has collaborations with Lonza Ltd. for the manufacture of COVID-19 vaccine; and Catalent Inc., Laboratorios Farmacéuticos Rovi, S.A., Recipharm, and Lonza Group for fill-finish manufacturing of its COVID-19 vaccine candidate, as well as Aldevron, LLC for supporting COVID-19 vaccine and additional programs in company's clinical development pipeline. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Latest GLS
- Gelesis Holdings Inc. filed SEC Form 8-K: Bankruptcy or Receivership, Leadership Update, Financial Statements and Exhibits
- SEC Form CT ORDER filed by Gelesis Holdings Inc.
- SEC Form SC 13D/A filed by Gelesis Holdings Inc. (Amendment)
- Gelesis Holdings Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Financial Statements and Exhibits
- SEC Form SC 13E3/A filed by Gelesis Holdings Inc. (Amendment)
- SEC Form PRER14A filed by Gelesis Holdings Inc.
- SEC Form SC 13D/A filed by Gelesis Holdings Inc. (Amendment)
- SEC Form 4 filed by Puretech Health Plc
- Gelesis Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- SEC Form SC 13E3/A filed by Gelesis Holdings Inc. (Amendment)
Latest MRNA
- Chief Financial Officer Mock James M converted options into 11,797 shares and covered exercise/tax liability with 5,704 shares, increasing direct ownership by 9% to 74,375 units (SEC Form 4) (for tax liability)
- Chief Legal Officer Klinger Shannon Thyme covered exercise/tax liability with 5,704 shares and converted options into 11,797 shares, increasing direct ownership by 8% to 81,340 units (SEC Form 4) (withholding obligation)
- Chief Legal Officer Klinger Shannon Thyme sold $485,766 worth of shares (3,471 units at $139.95) as part of a pre-agreed trading plan, covered exercise/tax liability with 1,048 shares and exercised 5,637 shares at a strike of $19.06, increasing direct ownership by 2% to 75,247 units (SEC Form 4) to cover withholding tax
- Chief Financial Officer Mock James M covered exercise/tax liability with 1,197 shares and converted options into 2,475 shares, increasing direct ownership by 2% to 68,282 units (SEC Form 4) (for withholding tax)
- President Hoge Stephen converted options into 9,283 shares and covered exercise/tax liability with 4,489 shares, increasing direct ownership by 0.32% to 1,489,699 units (SEC Form 4) (tax liability)
- Moderna downgraded by Rothschild & Co Redburn with a new price target
- Moderna Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement
- Moderna to Present at Upcoming Conferences in September 2026
- President Hoge Stephen converted options into 2,048 shares and covered exercise/tax liability with 991 shares, increasing direct ownership by 0.07% to 1,484,905 units (SEC Form 4) to satisfy tax liability
- Chief Legal Officer Klinger Shannon Thyme converted options into 1,103 shares and covered exercise/tax liability with 535 shares, increasing direct ownership by 0.77% to 74,129 units (SEC Form 4) to cover withholding tax